Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Galinpepimut S - SELLAS Life Sciences Group

Next Previous
X
Search
Drug Profile

Galinpepimut S - SELLAS Life Sciences Group

Alternative Names: 3D-189; FPI-01; GPS-Memorial-Sloan-Kettering-Cancer-Center/Sellas-Life-Sciences-Group; SLS-001; WT-1 analog peptide vaccine-Memorial-Sloan-Kettering; WT-1-analogue-peptide-vaccine-Memorial-Sloan-Kettering; WT1 cancer vaccine - SELLAS Life Sciences; WT1 peptide vaccine - Memorial Sloan Kettering; WT1 vaccine - Memorial Sloan Kettering; WT1-cancer-vaccine-Memorial-Sloan-Kettering; WT1-peptide-vaccine-Sellas-Life-Sciences-Group; ZELTHERVA

Latest Information Update: 17 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer 3D Medicines; Bristol-Myers Squibb; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme Corp.; Sellas Life Sciences Group
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant-mesothelioma; Acute myeloid leukaemia; Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Cancer; Malignant-mesothelioma; Multiple myeloma; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I Fallopian tube cancer; Haematological malignancies; Peritoneal cancer

Most Recent Events

  • 15 Oct 2024 US FDA grants Rare Pediatric Disease Designation to Galinpepimut S for the treatment of Acute Myeloid Leukemia
  • 31 May 2024 Adverse events and efficacy data from a phase I trial in Malignant mesothelioma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 29 Apr 2024 Sellas Life Sciences anticipates to meet with the Independent Data Monitoring Committee (IDMC) in June 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top